Guizhou Xinbang Pharmaceutical Co., Ltd.
Símbolo: 002390.SZ
SHZ
3.89
CNYPrecio de mercado actual
32.8887
Ratio PER
-2.3022
Ratio PEG
7.06B
Capitalización MRK
- 0.01%
Rendimiento DIV
Guizhou Xinbang Pharmaceutical Co., Ltd. (002390-SZ) Estados Financieros
Balance de situación
common:word.in-mln USD Growth | TTM | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
balance-sheet.row.cash-and-short-term-investments | 0 | 899.2 | 624.6 | 1776.4 | |||||||||||||||||
balance-sheet.row.short-term-investments | 0 | 0 | 0 | 0 | |||||||||||||||||
balance-sheet.row.net-receivables | 0 | 3870.6 | 4011.3 | 3466.8 | |||||||||||||||||
balance-sheet.row.inventory | 0 | 1032.7 | 935.7 | 843.4 | |||||||||||||||||
balance-sheet.row.other-current-assets | 0 | 3.7 | 4.7 | 4.6 | |||||||||||||||||
balance-sheet.row.total-current-assets | 0 | 5806.2 | 5576.4 | 6091.1 | |||||||||||||||||
balance-sheet.row.property-plant-equipment-net | 0 | 2671.7 | 2705.9 | 2323.2 | |||||||||||||||||
balance-sheet.row.goodwill | 0 | 607.3 | 607.3 | 605.5 | |||||||||||||||||
balance-sheet.row.intangible-assets | 0 | 204.4 | 217.6 | 219.6 | |||||||||||||||||
balance-sheet.row.goodwill-and-intangible-assets | 0 | 811.7 | 825 | 825.1 | |||||||||||||||||
balance-sheet.row.long-term-investments | 0 | 343.8 | 347.4 | 223 | |||||||||||||||||
balance-sheet.row.tax-assets | 0 | 62.4 | 55.6 | 46.5 | |||||||||||||||||
balance-sheet.row.other-non-current-assets | 0 | 97.2 | 118.4 | 153.2 | |||||||||||||||||
balance-sheet.row.total-non-current-assets | 0 | 3986.9 | 4052.3 | 3571 | |||||||||||||||||
balance-sheet.row.other-assets | 0 | 0 | 0 | 0 | |||||||||||||||||
balance-sheet.row.total-assets | 0 | 9793.1 | 9628.6 | 9662.2 | |||||||||||||||||
balance-sheet.row.account-payables | 0 | 977.2 | 993.4 | 788.6 | |||||||||||||||||
balance-sheet.row.short-term-debt | 0 | 1345.8 | 1362.3 | 3382.5 | |||||||||||||||||
balance-sheet.row.tax-payables | 0 | 33.3 | 37.4 | 32.2 | |||||||||||||||||
balance-sheet.row.long-term-debt-total | 0 | 22 | 24.8 | 24.5 | |||||||||||||||||
Deferred Revenue Non Current | 0 | 18.9 | 20.4 | 22.9 | |||||||||||||||||
balance-sheet.row.deferred-tax-liabilities-non-current | 0 | - | - | - | |||||||||||||||||
balance-sheet.row.other-current-liab | 0 | 330.6 | 6.5 | 4.6 | |||||||||||||||||
balance-sheet.row.total-non-current-liabilities | 0 | 41.2 | 45.5 | 23.2 | |||||||||||||||||
balance-sheet.row.other-liabilities | 0 | 0 | 0 | 0 | |||||||||||||||||
balance-sheet.row.capital-lease-obligations | 0 | 22 | 24.8 | 24.5 | |||||||||||||||||
balance-sheet.row.total-liab | 0 | 2728 | 2800.1 | 4493.7 | |||||||||||||||||
balance-sheet.row.preferred-stock | 0 | 0 | 0 | 0 | |||||||||||||||||
balance-sheet.row.common-stock | 0 | 1943.9 | 2027.2 | 1667.2 | |||||||||||||||||
balance-sheet.row.retained-earnings | 0 | 373.2 | 271.5 | 28 | |||||||||||||||||
balance-sheet.row.accumulated-other-comprehensive-income-loss | 0 | 189.6 | 102.7 | 57.3 | |||||||||||||||||
balance-sheet.row.other-total-stockholders-equity | 0 | 4301.7 | 4218.4 | 3165.9 | |||||||||||||||||
balance-sheet.row.total-stockholders-equity | 0 | 6808.5 | 6619.8 | 4918.3 | |||||||||||||||||
balance-sheet.row.total-liabilities-and-stockholders-equity | 0 | 9793.1 | 9628.6 | 9662.2 | |||||||||||||||||
balance-sheet.row.minority-interest | 0 | 256.6 | 208.7 | 250.2 | |||||||||||||||||
balance-sheet.row.total-equity | 0 | 7065 | 6828.5 | 5168.5 | |||||||||||||||||
balance-sheet.row.total-liabilities-and-total-equity | 0 | - | - | - | |||||||||||||||||
Total Investments | 0 | 343.8 | 347.4 | 223 | |||||||||||||||||
balance-sheet.row.total-debt | 0 | 1367.8 | 1387.1 | 3382.5 | |||||||||||||||||
balance-sheet.row.net-debt | 0 | 468.6 | 762.5 | 1606.1 |
Estado de tesorería
common:word.in-mln USD Growth | TTM | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
cash-flows.row.net-income | 0 | 268.4 | 374 | 220.6 | |||||||||||||||||
cash-flows.row.depreciation-and-amortization | 0 | 243.5 | 247.3 | 231.6 | |||||||||||||||||
cash-flows.row.deferred-income-tax | 0 | -6.8 | -9.1 | 6.4 | |||||||||||||||||
cash-flows.row.stock-based-compensation | 0 | 31.5 | 6 | -6.4 | |||||||||||||||||
cash-flows.row.change-in-working-capital | 0 | -117.1 | -338.6 | 74.8 | |||||||||||||||||
cash-flows.row.account-receivables | 0 | 95 | -609.8 | 348.1 | |||||||||||||||||
cash-flows.row.inventory | 0 | -97 | -92.3 | 150.9 | |||||||||||||||||
cash-flows.row.account-payables | 0 | -108.3 | 372.6 | -430.6 | |||||||||||||||||
cash-flows.row.other-working-capital | 0 | -6.8 | -9.1 | 6.4 | |||||||||||||||||
cash-flows.row.other-non-cash-items | 0 | 171.3 | 178.4 | 215 | |||||||||||||||||
cash-flows.row.net-cash-provided-by-operating-activities | 0 | 0 | 0 | 0 | |||||||||||||||||
cash-flows.row.investments-in-property-plant-an-equipment | 0 | -158.8 | -253.8 | -138.1 | |||||||||||||||||
cash-flows.row.acquisitions-net | 0 | 1.6 | -295.5 | 566.1 | |||||||||||||||||
cash-flows.row.purchases-of-investments | 0 | -12.4 | -1719.6 | -1516.5 | |||||||||||||||||
cash-flows.row.sales-maturities-of-investments | 0 | 51 | 1523.6 | 1494.7 | |||||||||||||||||
cash-flows.row.other-investing-activites | 0 | 0.5 | 0.9 | 1.7 | |||||||||||||||||
cash-flows.row.net-cash-used-for-investing-activites | 0 | -118 | -744.3 | 408 | |||||||||||||||||
cash-flows.row.debt-repayment | 0 | -2019.5 | -4257 | -3561.4 | |||||||||||||||||
cash-flows.row.common-stock-issued | 0 | 0 | 0 | 86.2 | |||||||||||||||||
cash-flows.row.common-stock-repurchased | 0 | 0 | 0 | -86.2 | |||||||||||||||||
cash-flows.row.dividends-paid | 0 | -168.4 | -230.3 | -197.6 | |||||||||||||||||
cash-flows.row.other-financing-activites | 0 | 1998.4 | 3576.7 | 3171.8 | |||||||||||||||||
cash-flows.row.net-cash-used-provided-by-financing-activities | 0 | -189.4 | -910.6 | -587.2 | |||||||||||||||||
cash-flows.row.effect-of-forex-changes-on-cash | 0 | 0 | 0 | 2.3 | |||||||||||||||||
cash-flows.row.net-change-in-cash | 0 | 283.4 | -1196.9 | 565.2 | |||||||||||||||||
cash-flows.row.cash-at-end-of-period | 0 | 797 | 513.7 | 1710.6 | |||||||||||||||||
cash-flows.row.cash-at-beginning-of-period | 0 | 513.7 | 1710.6 | 1145.4 | |||||||||||||||||
cash-flows.row.operating-cash-flow | 0 | 590.8 | 458 | 742.1 | |||||||||||||||||
cash-flows.row.capital-expenditure | 0 | -158.8 | -253.8 | -138.1 | |||||||||||||||||
cash-flows.row.free-cash-flow | 0 | 432 | 204.2 | 604 |
Fila de la Cuenta de Resultados
common:word.in-mln USD Growth | TTM | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
income-statement-row.row.total-revenue | 0 | 6350 | 6471.9 | 5845.6 | |||||||||||||||||
income-statement-row.row.cost-of-revenue | 0 | 5133.1 | 5119.4 | 4593.5 | |||||||||||||||||
income-statement-row.row.gross-profit | 0 | 1217 | 1352.5 | 1252.1 | |||||||||||||||||
income-statement-row.row.gross-profit-ratio | 0 | 0 | 0 | 0 | |||||||||||||||||
income-statement-row.row.research-development | 0 | - | - | - | |||||||||||||||||
income-statement-row.row.selling-general-administrative | 0 | - | - | - | |||||||||||||||||
income-statement-row.row.selling-and-marketing-expenses | 0 | - | - | - | |||||||||||||||||
income-statement-row.row.other-expenses | 0 | 292 | 297.8 | 268.3 | |||||||||||||||||
income-statement-row.row.operating-expenses | 0 | 836.4 | 787.1 | 802.1 | |||||||||||||||||
income-statement-row.row.cost-and-expenses | 0 | 5969.5 | 5906.5 | 5395.7 | |||||||||||||||||
income-statement-row.row.interest-income | 0 | 13.5 | 14 | 15.4 | |||||||||||||||||
income-statement-row.row.interest-expense | 0 | 51.8 | 100.2 | 99.6 | |||||||||||||||||
income-statement-row.row.selling-and-marketing-expenses | 0 | - | - | - | |||||||||||||||||
income-statement-row.row.total-other-income-expensenet | 0 | -114.4 | -30.4 | -162.5 | |||||||||||||||||
income-statement-row.row.ebitda-ratio-caps | 0 | - | - | - | |||||||||||||||||
income-statement-row.row.other-operating-expenses | 0 | 292 | 297.8 | 268.3 | |||||||||||||||||
income-statement-row.row.total-operating-expenses | 0 | -114.4 | -30.4 | -162.5 | |||||||||||||||||
income-statement-row.row.interest-expense | 0 | 51.8 | 100.2 | 99.6 | |||||||||||||||||
income-statement-row.row.depreciation-and-amortization | 0 | 243.5 | 347.7 | 231.6 | |||||||||||||||||
income-statement-row.row.ebitda-caps | 0 | - | - | - | |||||||||||||||||
income-statement-row.row.operating-income | 0 | 427.8 | 451.5 | 429.9 | |||||||||||||||||
income-statement-row.row.income-before-tax | 0 | 313.4 | 421.1 | 267.5 | |||||||||||||||||
income-statement-row.row.income-tax-expense | 0 | 45 | 47.2 | 46.9 | |||||||||||||||||
income-statement-row.row.net-income | 0 | 224.5 | 374 | 173.5 |
Preguntas frecuentes
Cuánto es Guizhou Xinbang Pharmaceutical Co., Ltd. (002390.SZ) activos totales?
Guizhou Xinbang Pharmaceutical Co., Ltd. (002390.SZ) los activos totales son 9793091573.000.
¿Cuáles son los ingresos anuales de la empresa?
Los ingresos anuales son N/A.
¿Cuál es el margen de beneficios de la empresa?
El margen de beneficios de la empresa es 0.190.
¿Qué es el flujo de caja libre de la empresa?
El flujo de caja libre es 0.334.
¿Cuál es el margen de beneficio neto de la empresa?
El margen de beneficio neto es 0.037.
¿Cuáles son los ingresos totales de la empresa?
Los ingresos totales son 0.053.
¿Qué es Guizhou Xinbang Pharmaceutical Co., Ltd. (002390.SZ) beneficio neto (ingresos netos)?
El beneficio neto (ingresos netos) es 224479086.000.
¿Cuál es la deuda total de la empresa?
La deuda total es 1367777175.000.
¿Cuál es la cifra de gastos de explotación?
Los gastos de explotación son 836448131.000.
¿Cuál es la cifra de tesorería de la empresa?
La tesorería de la empresa es 0.000.